Guidance, NICE advice and quality standards in development | Guidance

Showing 21 to 30 of 437

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]	Technology appraisal guidance	TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]	Technology appraisal guidance	TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]	Technology appraisal guidance	TBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]	Technology appraisal guidance	TBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]	Technology appraisal guidance	TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]	Technology appraisal guidance	TBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]	Technology appraisal guidance	TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]	Technology appraisal guidance	TBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]	Technology appraisal guidance	TBC